Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis

Journal of Pediatric Surgery

Volumn 44, Issue 1, 2009, Pages 204-211

  Sims Jr , Thomas L ^a,b   Hamner, J Blair ^a,b   Bush, Rebecca A ^a   Fischer, Peter E ^b   Kim, Seung U ^c   Aboody, Karen S ^d   McCarville, Beth ^a   Danks, Mary K ^a   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bone metastasis; Neural progenitor cells; Neuroblastoma; Osteoclast; Osteoprotegerin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; LUCIFERASE; OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE MARROW; BONE METASTASIS; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NEURAL STEM CELL; NEUROBLASTOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCID MOUSE; TREATMENT RESPONSE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; X RAY;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEUROBLASTOMA; OSTEOPROTEGERIN; STATISTICS, NONPARAMETRIC; STEM CELLS; TRANSDUCTION, GENETIC;

EID: 58149514116     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2008.10.041     Document Type: Article

References (26)

1. Miller R.W., Young Jr. J.L., and Novakovic B. Childhood cancer. Cancer 75 1 Suppl (1995) 395-405
2. Black C.T. Neuroblastoma. In: Andrassy R.J. (Ed). Pediatric Surgical Oncology (1998), W.B. Saunders, Philadelphia (Pa) 175-211
3. Roodman G.D. Biology of osteoclast activation in cancer. J Clin Oncol 19 (2001) 3562-3571
4. Sohara Y., Shimada H., and DeClerck Y.A. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett 228 (2005) 203-209
5. Guise T.A., and Mundy G.R. Cancer and bone. Endocr Rev 19 (1998) 18-54
6. Wittrant Y., Theoleyre S., Chipoy C., et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704 (2004) 49-57
7. Michigami T., Ihara-Watanabe M., Yamazaki M., et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61 (2001) 1637-1644
8. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
9. Body J.J., Greipp P., Coleman R.E., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 3 Suppl (2003) 887-892
10. Keller E.T., Dai J., Escara-Wilke J., et al. New trends in the treatment of bone metastasis. J Cell Biochem 102 (2007) 1095-1102
11. Granchi D., Amato I., Battistelli L., et al. In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 111 (2004) 829-838
12. Aboody K.S., Najbauer J., Schmidt N.O., et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol 8 (2006) 119-126
13. Bendetti S., Pirola B., Pollo B., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6 (2000) 447-450
14. Brown A., Yang W., Schmidt N., et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Therapy 14 (2003) 1777-1785
15. Aboody K., Brown A., Rainov N., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97 (2000) 12846-12851
16. Danks M.K., Yoon K.J., Bush R., et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 67 (2007) 22-25
17. Dickson P.V., Hamner J.B., Burger R., et al. Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-b and restricts tumor growth in a murine model of disseminated neuroblastoma. J Pediatr Surg 42 (2007) 48-53
18. Kim S., Nakagawa E., Hatori K., et al. Production of immortalized human neural crest stem cells. Methods Mol Biol 198 (2002) 55-65
19. Dickson P.V., Hamner B., Ng C.Y., et al. In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg 42 (2007) 1172-1179
20. Dickson P.V., Hamner J.B., Cauthen L.A., et al. Efficacy of zoledronate against neuroblastoma. Surgery 140 (2006) 227-235
21. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007) 3942-3950
22. Davidoff A.M., Ng C.Y., Zhang Y., et al. Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability. Mol Ther 11 (2005) 300-310
23. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 (1999) 2412-2424
24. Kong Y.Y., Boyle W.J., and Penninger J.M. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 77 (1999) 188-193
25. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998) 610-615
26. Canon J.R., Roudier M., Bryant R., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25 (2008) 119-129